Enliven Therapeutics has priced an upsized $400 million public offering of common stock and pre-funded warrants, with gross proceeds of about $400 million before fees, expected to close on June 15, 2026.
Jazz Pharmaceuticals reported that its confirmatory Phase 3 LAGOON trial for Zepzelca (lurbinectedin) in second-line small cell lung cancer failed to meet its primary overall survival endpoint, although the drug’s existing U.S. approvals are not immediately affected because the failed study was a confirmatory trial and not the basis for its current maintenance-line indication.
Sources:
Enliven Therapeutics prices $400M stock offering - ELVN
Jazz's lung cancer drug keeps approval despite failed trial
Jazz Pharma LAGOON trial misses survival goal - Stock Titan
Enliven Therapeutics Shares Rise After Pricing $400M Upsized Public Offering
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin ...
Enliven Therapeutics (ELVN) Upsizes Public Offering to $400 Mill
Zepzelca's pivotal surprise | ApexOnco - Oncology Pipeline
ELVN Secures $400M Offering Increase in Common Stock
Enliven Therapeutics (ELVN) Stock Surges On FDA, Trial Wins
Enliven Therapeutics Q1 2026 Earnings Report - MarketBeat
ELVN Stock Quote | Price Chart | Volume Chart Enliven Therapeutics